滤泡性淋巴瘤的靶向药物研究进展  

Advances in targeted drugs for follicular lymphoma

作　　者：杜晓艳[1] 王晶[1] 克晓燕[1] 

机构地区：[1]北京大学第三医院血液科,北京100191

出　　处：《现代肿瘤医学》2017年第20期3358-3360,共3页Journal of Modern Oncology

摘　　要：滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性淋巴瘤,在非霍奇金淋巴瘤(nonHodgkin's lymphoma,NHL)中发病率仅次于弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL),具有易向DLBCL转化、缓解后复发率高等特点。美罗华的问世明显改善了滤泡淋巴瘤患者的预后,但并没有改变FL患者易复发的结局。随着针对FL的治疗新靶点包括Bcl-2、PI3K、PD-1等发现及其机制的进一步阐明,针对相应靶点的新药也开始进入临床试验,为改善FL患者的预后提供了新的可能。Follicular lymphoma（FL） is the most common indolent lymphoma, and the incidence in non- Hodgkin＇s lymphoma（NHL） was second only to diffuse large B -cell lymphoma（ DLBCL）. FL is easy to transform to DLBCL and relapse after remission. The advent of rituximab significantly improved the prognosis of patients with follicular lympho- ma, but did not change the outcome of FL patients. With the discovery of new targets for FL, including Bcl -2, PI3 K and PD - 1, the new drugs targeting the target has begun to enter the clinical trial, which provides new possibilities to improve the quality of life for FL patients.

关 键 词：滤泡性淋巴瘤 新药 治疗靶点 

分 类 号：R733.4[医药卫生—肿瘤]